Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Liabilities and Shareholders Equity data on record, last reported at $577.1 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 25.23% year-over-year to $577.1 million; the TTM value through Dec 2025 reached $1.2 billion, down 57.53%, while the annual FY2024 figure was $742.4 million, 51.38% up from the prior year.
  • Liabilities and Shareholders Equity reached $577.1 million in Q3 2025 per VRDN's latest filing, down from $582.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $771.9 million in Q3 2024 and bottomed at $118.2 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $407.9 million, with a median of $410.9 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 573.73% in 2021, then fell 25.38% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $203.7 million in 2021, then skyrocketed by 113.58% to $435.1 million in 2022, then rose by 12.72% to $490.4 million in 2023, then soared by 51.38% to $742.4 million in 2024, then dropped by 22.26% to $577.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $577.1 million in Q3 2025, $582.3 million in Q2 2025, and $742.4 million in Q4 2024.